Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shubham Pant

Showing results (101-110 of 181) with videos related to

Pageof 19
Sort By:
Journal of Medical Internet Research|March 15, 2019
Cancer-Related Internet Use and Its Association With Patient Decision Making and Trust in Physicians Among Patients in an Early Drug Development Clinic: A Questionnaire-Based Cross-Sectional Observational StudyGoldy C George, Eucharia C Iwuanyanwu, Adrianna S Buford, et al.
Annals of Surgery|March 20, 2024
Trends Over Time in Recurrence Patterns and Survival Outcomes after Neoadjuvant Therapy and Surgery for Pancreatic CancerSamuel H Cass, Ching-Wei D Tzeng, Laura R Prakash, et al.
Future Oncology (London, England)|November 8, 2024
Sitravatinib in patients with solid tumors selected by molecular alterations: results from a Phase Ib studyLyudmila Bazhenova, Dong-Wan Kim, Byoung Chul Cho, et al.
Cancer Research Communications|April 16, 2026
BI 905711, a TRAILR2/CDH17 Bispecific Antibody, Alone or with Chemotherapy for Patients with Advanced Gastrointestinal Cancers: Phase I Study FindingsJames J Harding, Ralf Hofheinz, Elena Élez, et al.
Cancer Chemotherapy and Pharmacology|June 14, 2023
A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutationSarina A Piha-Paul, Chieh Tseng, Hai T Tran, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 22, 2017
Insurance Clearance for Early-Phase Oncology Clinical Trials Following the Affordable Care ActKenneth L Kehl, Cheryl P Fullmer, Siqing Fu, et al.
Annals of Surgical Oncology|April 9, 2020
The Sequential Radiographic Effects of Preoperative Chemotherapy and (Chemo)Radiation on Tumor Anatomy in Patients with Localized Pancreatic CancerGiampaolo Perri, Laura Prakash, Giuseppe Malleo, et al.
Investigational New Drugs|April 4, 2018
A phase I, open-label, two-stage study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral AKT inhibitor GSK2141795 in patients with solid tumorsCarol Aghajanian, Katherine M Bell-McGuinn, Howard A Burris, et al.
Cancer Research Communications|December 21, 2023
Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid MalignanciesVivek Subbiah, Niamh Coleman, Sarina A Piha-Paul, et al.
The Oncologist|February 28, 2026
Phase I Trial of Binimetinib Plus Hydroxychloroquine in Patients with Previously Treated Metastatic Pancreatic CancerS Daniel Haldar, Fen Saj, So Jung Hong, et al.
Pageof 19

Showing results (101-110 of 181) with videos related to

Sort By:
Pageof 19
Journal of Medical Internet Research|March 15, 2019
Cancer-Related Internet Use and Its Association With Patient Decision Making and Trust in Physicians Among Patients in an Early Drug Development Clinic: A Questionnaire-Based Cross-Sectional Observational StudyGoldy C George, Eucharia C Iwuanyanwu, Adrianna S Buford, et al.
Annals of Surgery|March 20, 2024
Trends Over Time in Recurrence Patterns and Survival Outcomes after Neoadjuvant Therapy and Surgery for Pancreatic CancerSamuel H Cass, Ching-Wei D Tzeng, Laura R Prakash, et al.
Future Oncology (London, England)|November 8, 2024
Sitravatinib in patients with solid tumors selected by molecular alterations: results from a Phase Ib studyLyudmila Bazhenova, Dong-Wan Kim, Byoung Chul Cho, et al.
Cancer Research Communications|April 16, 2026
BI 905711, a TRAILR2/CDH17 Bispecific Antibody, Alone or with Chemotherapy for Patients with Advanced Gastrointestinal Cancers: Phase I Study FindingsJames J Harding, Ralf Hofheinz, Elena Élez, et al.
Cancer Chemotherapy and Pharmacology|June 14, 2023
A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutationSarina A Piha-Paul, Chieh Tseng, Hai T Tran, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 22, 2017
Insurance Clearance for Early-Phase Oncology Clinical Trials Following the Affordable Care ActKenneth L Kehl, Cheryl P Fullmer, Siqing Fu, et al.
Annals of Surgical Oncology|April 9, 2020
The Sequential Radiographic Effects of Preoperative Chemotherapy and (Chemo)Radiation on Tumor Anatomy in Patients with Localized Pancreatic CancerGiampaolo Perri, Laura Prakash, Giuseppe Malleo, et al.
Investigational New Drugs|April 4, 2018
A phase I, open-label, two-stage study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral AKT inhibitor GSK2141795 in patients with solid tumorsCarol Aghajanian, Katherine M Bell-McGuinn, Howard A Burris, et al.
Cancer Research Communications|December 21, 2023
Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid MalignanciesVivek Subbiah, Niamh Coleman, Sarina A Piha-Paul, et al.
The Oncologist|February 28, 2026
Phase I Trial of Binimetinib Plus Hydroxychloroquine in Patients with Previously Treated Metastatic Pancreatic CancerS Daniel Haldar, Fen Saj, So Jung Hong, et al.
Pageof 19